Philip van Doorn

Deep Dive Archives | Email alerts

Feb. 28, 2020, 9:39 a.m. EST

These are the only 7 stocks in the S&P 500 that rose while the market plunged

The company whose stock has risen the most is working on drug trials to fight COVID-19

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    S&P 500 Index (SPX)
  • X
    Tesla Inc. (TSLA)
  • X
    Gilead Sciences Inc. (GILD)

or Cancel Already have a watchlist? Log In

By Philip van Doorn, MarketWatch


Bloomberg News
Gilead Sciences is holding drug trials to see if its Remdesivir medication is effective against the COVID-10 virus.

In any market environment, there are exceptions to the trend. But there aren’t many this time.

Since the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.19%  hit its last closing record on Feb. 19, the index has skidded 12% — and only seven of the component stocks haven’t declined through the close on Feb. 27. See the list below.

Before you get there, here’s a list of stocks in the index that took the worst beatings, along with a summary of how the 11 sectors performed.

It might surprise you that Tesla /zigman2/quotes/203558040/composite TSLA -5.42%  isn’t on that list of decliners, but the electric car maker hasn’t yet met the requirements to be included in the S&P 500. Before the outbreak of the coronavirus strain known as COVID-19, it appeared likely to be added to the index by the end of 2020. Tesla’s stock was down nearly $100 (13%) on Feb. 27 to close at $679. The stock was down $238 (26%) since it set a closing record of $917.42 on Feb. 19.

Read: Tesla’s stock tumbles toward biggest-ever weekly drop

So here are the exceptions — seven S&P 500 stocks that rose in price between Feb. 19 and Feb. 27:

Company Ticker Industry Price change since Feb. 19 Price change - 2020 Decline from 52-week high Price change - 2019
Gilead Sciences Inc. /zigman2/quotes/210293917/composite GILD Biotechnology 7.9% 11.8% -7.9% 3.9%
Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN Biotechnology 7.7% 14.9% -8.2% 0.5%
Clorox Co. /zigman2/quotes/206443229/composite CLX Household/Personal Care 2.3% 9.9% -3.1% -0.4%
E-Trade Financial Corp. Investment Banks/Brokers 2.3% 1.3% -19.8% 3.4%
CME Group Inc. Class A /zigman2/quotes/210449693/composite CME Investment Banks/Brokers 1.4% 4.8% -6.6% 6.7%
Newmont Corp. /zigman2/quotes/205356474/composite NEM Precious Metals 0.8% 7.1% -9.4% 25.4%
Cboe Global Markets Inc. /zigman2/quotes/208166986/composite CBOE Investment Banks/Brokers 0.7% 1.0% -5.2% 22.7%
Source: FactSet

You can click the tickers for more about each company.

• Gilead Sciences /zigman2/quotes/210293917/composite GILD +0.64%  has announced two Phase 3 clinical studies to measure the effectiveness of its Remdesivir medication in countering COVID-19 infections. The company’s Feb. 26 press release has more details. Jefferies analyst Michael Yee rates Gilead a “buy,” but wrote in a note to clients on Feb. 26 that although he is pleased that fighting the virus is a ‘very high priority” for Gilead’s management, “the financial implications are modest (pricing, one-time use, no tail).”

• Regeneron Pharmaceuticals /zigman2/quotes/203149337/composite REGN +2.05%  ws upgraded to a “Buy” by Jefferies analyst Biren Amin on Feb. 25, because he believes competitive risk to the company’s Eylea macular degeneration therapy has been minimized because of safety concerns over Novartis AG’s /zigman2/quotes/203243705/composite NVS +1.54%   /zigman2/quotes/203286410/delayed CH:NOVN -0.20%  Beovu medication.

• Clorox /zigman2/quotes/206443229/composite CLX +1.42%  is an obvious defensive stock during a time when people are concerned about the spread of a deadly virus and reaching for bleach. But Charles Lemonides, founder of ValueWorks LLC in New York, argued that for long-term investors, Clorox’s high valuation to earnings actually makes it a risky stock.

• E-Trade Financial  agreed on Feb. 20 to be acquired by Morgan Stanley /zigman2/quotes/209104354/composite MS +1.47%  in an all-stock deal valued at $58.74 a share at that time. E-Trade’s shares closed at $45.95 Thursday. The deal calls for an exchange of 1.0432 Morgan Stanley shares for every E-Trade share. Morgan Stanley’s shares closed at $45.41 on Feb. 27, so based on those numbers, E-Trade’s takeout price would be $47.37.

<STRONG>Create an email alert for Philip van Doorn’s Deep Dive columns <INTERNAL-PAGE URL="/tools/alerts/newsColumn.asp">here</INTERNAL-PAGE>.</STRONG>

/zigman2/quotes/210599714/realtime
US : S&P US
3,795.32
+44.55 +1.19%
Volume: 561.51M
Jan. 28, 2021 10:04a
loading...
/zigman2/quotes/203558040/composite
US : U.S.: Nasdaq
$ 817.30
-46.86 -5.42%
Volume: 6.52M
Jan. 28, 2021 10:04a
P/E Ratio
1,643
Dividend Yield
N/A
Market Cap
$819.14 billion
Rev. per Employee
$511,871
loading...
/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 65.90
+0.42 +0.64%
Volume: 682,932
Jan. 28, 2021 10:04a
P/E Ratio
68.35
Dividend Yield
4.13%
Market Cap
$82.08 billion
Rev. per Employee
$1.89M
loading...
/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 526.15
+10.59 +2.05%
Volume: 119,805
Jan. 28, 2021 10:04a
P/E Ratio
19.22
Dividend Yield
N/A
Market Cap
$55.01 billion
Rev. per Employee
$970,790
loading...
/zigman2/quotes/206443229/composite
US : U.S.: NYSE
$ 225.34
+3.16 +1.42%
Volume: 214,693
Jan. 28, 2021 10:04a
P/E Ratio
24.93
Dividend Yield
1.98%
Market Cap
$28.01 billion
Rev. per Employee
$763,750
loading...
/zigman2/quotes/210449693/composite
US : U.S.: Nasdaq
$ 181.80
+3.01 +1.68%
Volume: 123,734
Jan. 28, 2021 10:04a
P/E Ratio
30.16
Dividend Yield
1.88%
Market Cap
$64.18 billion
Rev. per Employee
$1.12M
loading...
/zigman2/quotes/205356474/composite
US : U.S.: NYSE
$ 59.93
+1.04 +1.77%
Volume: 874,730
Jan. 28, 2021 10:04a
P/E Ratio
18.96
Dividend Yield
2.66%
Market Cap
$47.31 billion
Rev. per Employee
$307,785
loading...
/zigman2/quotes/208166986/composite
US : U.S.: Cboe BZX
$ 92.50
+0.94 +1.03%
Volume: 59,346
Jan. 28, 2021 10:02a
P/E Ratio
21.58
Dividend Yield
1.71%
Market Cap
$9.89 billion
Rev. per Employee
$3.03M
loading...
/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 65.90
+0.42 +0.64%
Volume: 682,932
Jan. 28, 2021 10:04a
P/E Ratio
68.35
Dividend Yield
4.13%
Market Cap
$82.08 billion
Rev. per Employee
$1.89M
loading...
/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 526.15
+10.59 +2.05%
Volume: 119,805
Jan. 28, 2021 10:04a
P/E Ratio
19.22
Dividend Yield
N/A
Market Cap
$55.01 billion
Rev. per Employee
$970,790
loading...
/zigman2/quotes/203243705/composite
US : U.S.: NYSE
$ 94.33
+1.43 +1.54%
Volume: 155,467
Jan. 28, 2021 10:04a
P/E Ratio
26.59
Dividend Yield
2.33%
Market Cap
$207.75 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/203286410/delayed
CH : Switzerland: SWX
CHF 83.65
-0.17 -0.20%
Volume: 3.91M
Jan. 28, 2021 3:49p
P/E Ratio
25.31
Dividend Yield
3.53%
Market Cap
CHF184.80 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/206443229/composite
US : U.S.: NYSE
$ 225.34
+3.16 +1.42%
Volume: 214,693
Jan. 28, 2021 10:04a
P/E Ratio
24.93
Dividend Yield
1.98%
Market Cap
$28.01 billion
Rev. per Employee
$763,750
loading...
/zigman2/quotes/209104354/composite
US : U.S.: NYSE
$ 69.07
+1.00 +1.47%
Volume: 1.37M
Jan. 28, 2021 10:04a
P/E Ratio
10.72
Dividend Yield
2.03%
Market Cap
$123.84 billion
Rev. per Employee
N/A
loading...

Philip van Doorn covers various investment and industry topics. He has previously worked as a senior analyst at TheStreet.com. He also has experience in community banking and as a credit analyst at the Federal Home Loan Bank of New York.

This Story has 0 Comments
Be the first to comment
More News In
Markets

Story Conversation

Commenting FAQs »

Partner Center

World News from MarketWatch

Link to MarketWatch's Slice.